AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2016
Jan 6, 2016
29977_dirs_2016-01-06_6e6046bf-c5a8-4bad-b740-e584a52a450d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2016-01-04
Reporting Person: POON CHRISTINE A (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-01-04 | Non-Qualified Stock Option (right to buy) | $520.01 | A | 9212.0 | Acquired | 2026-01-04 | Common Stock (9212) | Direct |
Footnotes
F1: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Earnings Release
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Earnings Release
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3